Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage biotechnology company headquartered in Tampa, Florida, focused on the discovery and development of small molecule therapeutics for neurodegenerative and neuroinflammatory disorders. Leveraging a proprietary platform that targets protein trafficking and translational dysregulation, Annovis aims to restore cellular homeostasis by modulating the production and clearance of disease-related proteins. The company’s pipeline is designed to address critical pathways implicated in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and other central nervous system conditions.
The company’s lead asset, ANVS401 (Posiphen®), is an oral small molecule that has been evaluated in Phase 1 and Phase 2 clinical trials to reduce levels of amyloid precursor protein and its toxic fragments in Alzheimer’s patients. Preclinical studies suggest that this mechanism may also have applications in mitigating neuroinflammation. In addition to ANVS401, Annovis is advancing a second-generation program, ANVS520, which is aimed at lowering pathological tau and alpha-synuclein aggregates, key drivers of neurodegeneration in Alzheimer’s and Parkinson’s diseases. Both candidates reflect the company’s strategy of targeting multiple disease pathways with a single therapeutic approach.
Annovis Bio conducts its clinical trials in North America and Europe, collaborating with academic research centers and contract research organizations to explore safety, pharmacodynamics and biomarker endpoints. The company’s leadership team brings together expertise in neurology, medicinal chemistry and drug development, with a commitment to translating early-stage research into viable treatments. As a publicly traded entity, Annovis continues to engage with scientific and investor communities to advance its programs toward potential regulatory approval.
AI Generated. May Contain Errors.
Free ANVS Stock Alerts